On October 26, 2026 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, reported that it will participate in the following upcoming investor conferences in November and December 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UBS Global Biopharma Conference
Monday, November 16
11:20 AM GMT / 6:20 AM ET
London
Jefferies Global Healthcare Conference
Wednesday, November 18
9:30 AM GMT / 5:30 AM ET
London
Piper Sandler 38th Annual Healthcare Conference
Wednesday, December 2
Time TBD
New York
Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.

(Press release, Allogene, OCT 26, 2026, View Source [SID1234673857])